Publications

CXCR4 Enriched Umbilical Cord Blood Derived Treg Cells Preferentially Home To Resolve Bone Marrow Inflammation. Cytotherapy Vol. 25 Issue 6 Supplement S246-S247. May, 2023

https://www.isct-cytotherapy.org/article/S1465-3249(23)00616-3/fulltext

Allogeneic Umbilical Cord Blood Regulatory T Cells Decrease Inflammation And Preserve Anti-Tumor Activity of Car T Cells. Cytotherapy Vol. 25 Issue 6 Supplement S245-S246. May, 2023

https://www.isct-cytotherapy.org/article/S1465-3249(23)00615-1/fulltext

Adoptive Therapy with Off the Shelf, Allogeneic, Umbilical Cord Blood, Regulatory T Cells Show Safety in Amyotrophic Lateral Sclerosis. Cytotherapy Vol. 25 Issue 6 SupplementS33-S34. May, 2023

https://www.isct-cytotherapy.org/article/S1465-3249(23)00182-2/pdf

Phase Ib, open-label study of add on therapy with CK0804 in participants with myelofibrosis, with suboptimal response to ruxolitinib. J Clin Oncol 41, 2023 (suppl 16; abstr TPS7087) May 2023

https://meetings.asco.org/abstracts-presentations/225986

Randomized, Double Blinded, Placebo Controlled Trial of Allogeneic Cord Blood T-Regulatory Cell for Treatment of COVID-19 ARDS. Blood Adv. 2023 Mar 24

https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2022009619/495068/Randomized-Double-Blinded-Placebo-Controlled-Trial

Allogeneic cord blood regulatory T cells can resolve lung inflammation. Cytotherapy. 2023 Mar;25(3):245-253

https://pubmed.ncbi.nlm.nih.gov/36437190/

Regulatory T Cells Tested in Patients With COVID-19 ARDS. JAMA, vol. 324, no. 6, Aug. 2020, p. 539.

https://jamanetwork.com/journals/jama/fullarticle/2769243

Randomized, Multi-Center, Double-Blinded, Placebo Controlled Safety and Early Efficacy Trial of Cryopreserved Cord Blood Derived T-Regulatory Cell Infusions (CK0802) in the Treatment of COVID-19 Induced ARDS. (RESOLVE Trial). Blood, vol. 138, no. Supplement 1, Nov. 2021, pp. 828–828.

https://doi.org/10.1182/blood-2021-153616

Adoptive Therapy with Allogeneic Cord Blood T Regulatory Cells Improves Transfusion Requirement in Bone Marrow Failure Syndromes. Blood, vol. 138, no. Supplement 1, Nov. 2021, pp. 3875–3875

https://doi.org/10.1182/blood-2021-153864

Regulatory T Cells Tested in Patients With COVID-19 ARDS. JAMA, vol. 324, no. 6, Aug. 2020, p. 539.

https://doi.org/10.1001/jama.2020.13765

Regulatory T Cells for Treating Patients With COVID-19 and Acute Respiratory Distress Syndrome: Two Case Reports.” Annals of Internal Medicine, vol. 173, no. 10, Nov. 2020, pp. 852–53.

https://doi.org/10.7326/L20-0681

Adoptive Therapy with Allogeneic Cord Blood T Regulatory Cells Show Safety and Early Clinical Signal in Primary Myelofibrosis.” Blood, vol. 136, no. Supplement 1, Nov. 2020, pp. 41–42.

https://doi.org/10.1182/blood-2020-138585

Adoptive Therapy with Allogeneic Cord Blood T Regulatory Cells Show Safety and Early Clinical Signal in Primary Myelofibrosis.” Blood, vol. 136, no. Supplement 1, Nov. 2020, pp. 41–42.

https://doi.org/10.1182/blood-2020-138585

Adoptive Cord Blood T Regulatory Cell Therapy Leads to Resolution of Inflammation and Decreased Proteinuria in Lupus Nephritis.” Blood, vol. 136, no. Supplement 1, Nov. 2020, pp. 5–6.

https://doi.org/10.1182/blood-2020-140420

Adoptive Therapy with Cord Blood T Regulatory Cells Enhances Anti-Myeloma Efficacy of T Cell Based Immunotherapies.” Blood, vol. 136, no. Supplement 1, Nov. 2020, pp. 26–27.

https://doi.org/10.1182/blood-2020-143142

Combination of Cord Blood T Regulatory Cells with Ruxolitinib Decreases Side Effects and Improves Survival in Xenogenic Graft Vs. Host Disease.” Blood, vol. 136, no. Supplement 1, Nov. 2020, pp. 2–2.

https://doi.org/10.1182/blood-2020-140417

Cord Blood T Regulatory Cells Can Dampen Cytokine Release Syndrome and Improve on Target Efficacy of CD19 CAR T Cells.” Blood, vol. 136, no. Supplement 1, Nov. 2020, pp. 15–16.

https://doi.org/10.1182/blood-2020-138812

Novel CD4+CD8+ Umbilical Cord Blood Regulatory T Cells.” Blood, vol. 134, no. Supplement_1, Nov. 2019, pp. 4446–4446.

https://doi.org/10.1182/blood-2019-131948

Adoptive Therapy with Allogeneic Cord Blood T Regulatory Cells Show Safety and Early Clinical Signal in Primary Myelofibrosis.” Blood, vol. 136, no. Supplement 1, Nov. 2020, pp. 41–42.

https://doi.org/10.1182/blood-2020-138585

Phase I Clinical Trial of CK0801 (Cord Blood Regulatory T Cells) in Patients with Bone Marrow Failure Syndrome (BMF) Including Aplastic Anemia, Myelodysplasia and Myelofibrosis.” Blood, vol. 134, no. Supplement_1, Nov. 2019, pp. 1221–1221.

https://doi.org/10.1182/blood-2019-127702

Single Injection of Cord Blood Regulatory T Cells Can Delay the Manifestations of Systemic Lupus Erythematosus.” Blood, vol. 134, no. Supplement_1, Nov. 2019, pp. 1938–1938.

https://doi.org/10.1182/blood-2019-131436

Adoptive Therapy with Cord Blood Regulatory T Cells Can Treat Graft Vs Host Disease.” Blood, vol. 134, no. Supplement_1, Nov. 2019, pp. 1940–1940.

https://doi.org/10.1182/blood-2019-129395

Cord Blood Regulatory T Cells Prevent Mutiple Myeloma Progression By Suppressing Inflammation.” Blood, vol. 134, no. Supplement_1, Nov. 2019, pp. 3095–3095.

https://doi.org/10.1182/blood-2019-128418

Allogeneic Cord Blood Regulatory T Cells Can Prevent Graft Vs. Host Disease and Preserve Graft Vs Leukemia Effect: Update on Phase I/II Clinical Trial.” Blood, vol. 134, no. Supplement_1, Nov. 2019, pp. 4547–4547.

https://doi.org/10.1182/blood-2019-127726

Third Party, Umbilical Cord Blood Derived Regulatory T-Cells for Prevention of Graft versus Host Disease in Allogeneic Hematopoietic Stem Cell Transplantation: Feasibility, Safety and Immune Reconstitution.” Oncotarget, vol. 9, no. 86, Nov. 2018, pp. 35611–22.

https://doi.org/10.18632/oncotarget.26242

Ex Vivo Generation of Umbilical Cord Blood T Regulatory Cells Expressing the Homing Markers CD62L and Cutaneous Lymphocyte Antigen.” Oncotarget, vol. 9, no. 72, Sept. 2018, pp. 33694–701.

https://doi.org/10.18632/oncotarget.26097

Treg Adoptive Therapy: Is More Better?” Blood, vol. 127, no. 8, Feb. 2016, pp. 962–63.

https://doi.org/10.1182/blood-2015-12-682492

Is There an Expiration Date for a Cord Blood Unit in Storage?” Bone Marrow Transplantation, vol. 49, no. 8, Aug. 2014, pp. 1109–12.

https://doi.org/10.1038/bmt.2014.92

FOXP3 Is a Direct Target of MiR15a/16 in Umbilical Cord Blood Regulatory T Cells.” Bone Marrow Transplantation, vol. 49, no. 6, June 2014, pp. 793–99.

https://doi.org/10.1038/bmt.2014.57

Third-Party Umbilical Cord Blood–Derived Regulatory T Cells Prevent Xenogenic Graft-versus-Host Disease.” Cytotherapy, vol. 16, no. 1, Jan. 2014, pp. 90–100.

https://doi.org/10.1016/j.jcyt.2013.07.009

Dose Intensification of Busulfan in the Preparative Regimen Is Associated with Improved Survival: A Phase I/II Controlled, Randomized Study.” Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation, vol. 19, no. 3, Mar. 2013, pp. 474–80.

https://doi.org/10.1016/j.bbmt.2012.12.001

Novel Transplant Strategies for Generating Graft-versus-Leukemia Effect in Acute Myeloid Leukemia.” Current Opinion in Hematology, vol. 18, no. 2, Mar. 2011, pp. 98–104.

https://doi.org/10.1097/MOH.0b013e328343b858

Prophylaxis of Graft-Versus-Host Disease in Unrelated Donor Transplantation With Pentostatin, Tacrolimus, and Mini-Methotrexate: A Phase I/II Controlled, Adaptively Randomized Study.” Journal of Clinical Oncology, vol. 29, no. 3, Jan. 2011, pp. 294–302.

https://doi.org/10.1200/JCO.2010.30.6357

Donor-Recipient Mismatches in MHC Class I Chain-Related Gene A in Unrelated Donor Transplantation Lead to Increased Incidence of Acute Graft-versus-Host Disease.” Blood, vol. 114, no. 14, Oct. 2009, pp. 2884–87.

https://doi.org/10.1182/blood-2009-05-223172

Ex Vivo Expanded Umbilical Cord Blood T Cells Maintain Naive Phenotype and TCR Diversity.” Cytotherapy, vol. 8, no. 2, 2006, pp. 149–57.

https://doi.org/10.1080/14653240600620812